bilaterals.org logo
bilaterals.org logo

intellectual property


IP licence, trademarks and ISDS: Bridgestone v. Panama
Can an intellectual property right or a license authorizing its use be deemed an ‘investment’ under bilateral investment treaties?
Free trade agreement with Indonesia to be signed in Jakarta on 16 December
Indonesia - EFTA trade deal will be signed, 98 per cent of Swiss exports to Indonesia will be exempt from customs duties over the coming years.
Comments on negotiating objectives for a US-Japan trade agreement
US drug manufacturers want Japan to provide 12 years of data protection for biologic medicine in upcoming trade talks. That would be four more years than Japan currently provides.
Japan to extend copyright period on works including novels and paintings to 70 years on Dec. 30
The copyright period on works such as novels and paintings in Japan is set to be extended to 70 years after the authors’ deaths, from the current 50 years, as part of legislation to approve the TPP.
NAFTA 2.0: US-Mexico-Canada Agreement. Chapter 20: pharmaceutical related patent provisions
The Intellectual Property Chapter of the revised NAFTA, rebranded by the Trump Administration USMCA, includes provisions that threaten to undermine critical efforts to­wards affordable health care and medicine.
Indonesia and RCEP: Beware the public health risks
Proposals from Japan and South Korea would require patent law changes in several RCEP countries, including Indonesia.
Switzerland should stop pushing for TRIPS-plus measures in trade agreement with Indonesia
Swiss and Norwegians civil society groups addressed their serious concerns over TRIPS-plus provisions being included in the trade agreement under negotiation between the European Free Trade Association (EFTA) and Indonesia.
RCEP and affordable medicines: Civil society reaches out to Minister of Commerce Suresh Prabhu
Civil society organisations, patient groups and health activists have been concerned about intellectual property provisions being discussed in RCEP which undermine access to medicines and affordable treatment for patients
Indonesia-EFTA CEPA TRIPS-plus, threat for access to medicines and the right to health of millions of people in Indonesia
In many countries, the implementation of the TRIPS-plus measures has significantly increased the cost of medicines.
Drugs costs impact health
Canada’s negotiators extended data protection on biologics without knowing impact on prices.
UPOV 91 and trade agreements: Compromising farmers’ right to save and sell seeds
Increased effort to include references to UPOV 91 in EU trade agreements impose intellectual property rights on seeds, which can restrict the farmers’ right to save and re-use seeds and undermine local seed systems
Trade and patent changes could increase healthcare costs by $100bn, CPHI annual report warns
Patients may need to wait an extra five or 10 years to access generic medicines, which could raise healthcare costs by as $100 billion over the next five years, according to the latest CPhI annual report
Canada ’caved’ on intellectual property provisions in USMCA trade deal, experts say
Experts are fuming, saying USMCA will hamper Canada’s innovation economy and hike costs to the health care system over patented drugs.
US-Canada-Mexico trade agreement provisions on injunctions and damages
The damages provisions in the new trade agreement are dangerous, and create a norm that is in conflict with national laws.
Despite seed concerns, CPTPP study to proceed
Thai farmers and civil society organisations vented their concerns about the impact of the new pact’s IP chapter that prevents them from saving and reusing seeds that contain patented plant material.
Un accord de libre-échange Suisse-Indonésie serait à bout touchant
L’Indonésie n’exige plus l’abolition de droits de douane à l’importation de son huile de palme, produit contesté en Suisse, et accepte des règles strictes en matière de propriété intellectuelle.
Extended monopolies on biologic drugs – A warning to developing countries
The United States has throughout history been the principal demandeur of maximalist intellectual property, backed by a powerful pharmaceutical lobby.
RCEP talks: India manages major breakthrough
New Delhi won’t not take additional commitment on intellectual property rights beyond the TRIPS agreement it has already accepted at the WTO; investor-state dispute settlement (ISDS) mechanism only for limited sectors.
NAFTA deal close, but obstacles remain
US and Canada officials continue to meet but there are three key issues to resolve: dairy, intellectual property, dispute settlement.
New NAFTA could include tough intellectual property laws that Canada fought against in TPP
The new trade deal reached between the US and Mexico contains a myriad of rules and tariffs, and among them include tougher rules on copyright and intellectual property.